BIIB as of Nov 1 · 20:05 ET
BIIBNasdaqBiological Products, (No Diagnostic Substances)
Biogen Inc. · Brief
Next report
95 days
Feb 5 · before openest.Q4 FY26
Expected move
No implied move.
2 of 5≥ implied
- avg implied
- ±4.7%
- avg realized
- ±4.0%
Feb 12 '25—▼−4.28%—
May 1 '25—▼−0.12%—
Jul 31 '25±5.4%▲+1.07%×0.20
Oct 30 '25±4.9%▲+1.18%×0.24
Feb 6 '26±4.2%▲+8.53%×2.03
Q1 FY26±4.1%▲+6.00%×1.48
Q2 FY26—▲+1.76%—
Q3 FY26±4.7%▼−3.43%×0.74
quarterimplied−10%0+10%realized×
Q3 FY26±4.7%▼−3.43%×0.74
Q2 FY26—▲+1.76%—
Q1 FY26±4.1%▲+6.00%×1.48
Feb '26±4.2%▲+8.53%×2.03
Oct '25±4.9%▲+1.18%×0.24
Jul '25±5.4%▲+1.07%×0.20
2 older reports
May '25—▼−0.12%—
Feb '25—▼−4.28%—
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close
Bull & bear
Feb 5 report · est.—
Linked exposure
BIIB report sessionSuppliers 2
Customers 1
× = co-movement · max 501dSource: SEC filings · market data
Your note
privateThesis 0 · Decisions 0 · Observations 0
No thesis.